Australian women will gain improved access to affordable long-acting reversible contraceptives starting on November 1, 2023. The changes to the Medicare Benefits Schedule will benefit approximately 300,000 women annually, enabling them to save up to $400 in out-of-pocket costs. This initiative aims to enhance women’s reproductive health choices and address affordability issues that have hindered access to effective contraceptive methods.
Among the key updates, the contraceptive product NuvaRing, a soft plastic vaginal ring that releases hormones oestrogen and progestogen, will be listed on the Pharmaceutical Benefits Scheme for the first time. Typically costing over $270 each year, women will now pay $31.60 for a three-month supply or $7.70 if they qualify for concessional pricing. Furthermore, from January 1, 2024, the maximum price per script will decrease to $25.
Health Minister Mark Butler announced that the government will also invest in free training for health practitioners focusing on the insertion and removal of IUDs. This effort aims to increase the number of qualified practitioners and enhance access to these essential services. Butler emphasized the importance of these changes, stating, “For too long, women’s health needs were sidelined. The Albanese Government is changing that and delivering more choice, lower costs, and better health care.”
According to Butler, Australia currently has one of the lowest uptake rates of long-acting contraceptives among developed nations, a situation he attributes to both access and affordability challenges. He expressed optimism that the recent updates to the Medicare Benefits Schedule and expanded options through the Pharmaceutical Benefits Scheme will eliminate these barriers.
Women’s Minister Katy Gallagher echoed Butler’s sentiments, highlighting that the government’s goal is to provide Australian women with “genuine choice” over their reproductive health. She affirmed that this initiative would ensure choices are not limited by financial constraints or access issues.
This significant policy change marks a pivotal moment in women’s health in Australia, potentially reshaping the landscape of contraceptive access and affordability for many women. As the government pushes forward with these reforms, the impact on women’s health and autonomy will likely be closely monitored by stakeholders and advocates in the field.
